Q1 FY2026 · Presentation
69fe4469252cbf0ec174a43f_6c6e16e4975f5cd7e2f6091e84cde254_Phase 2 study to evaluate BHB-1893 in symptomatic nHCM · 16 pages
Read Braveheart Bio, Inc.'s results firsthand
Preview the first 2 pages of this presentation
Create a free account to start reading
Full documents are included with Professional